Patients who satisfy the eligibility criteria are randomised ( 1:1 ) to receive thalidomide ( 100-300mg daily ) plus dexamethasone ( 12mg/m ( 2 ) on days 1-4 of a 28-day cycle ) or placebo plus dexamethasone .